{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:54:02Z","timestamp":1791500042397,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16530-0","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:44:17Z","timestamp":1784090657000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical prognostic value of homologous recombination repair axis markers and PARP1 expression in breast cancer: a systematic review, meta-analysis, and independent cohort validation"],"prefix":"10.1186","volume":"26","author":[{"given":"Kezhen","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4417-9498","authenticated-orcid":false,"given":"Lei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"16530_CR1","first-page":"1","volume":"16","author":"NA Elhawary","year":"2025","unstructured":"Elhawary NA, Ekram SN, Sembawa HA, Tashkandi E, Bannani S, Azher ZA, Abumansour IS, Almuqati RM, Attieh R, Sindi IA, et al. Descriptive epidemiology of female breast cancer around the world: incidence, mortality, and sociodemographic risks and disparities. Int J Environ Health Res. 2025;16:1\u201315.","journal-title":"Int J Environ Health Res"},{"issue":"2","key":"16530_CR2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cpt.2025.07.001","volume":"4","author":"VK Dhiman","year":"2025","unstructured":"Dhiman VK, Kumari M, Singh D, Chemoresistance. The hidden barrier in cancer treatment. Cancer Pathog Ther. 2025;4(2):98\u2013109.","journal-title":"Cancer Pathog Ther"},{"key":"16530_CR3","doi-asserted-by":"publisher","first-page":"116584","DOI":"10.1016\/j.biopha.2024.116584","volume":"174","author":"P Huang","year":"2024","unstructured":"Huang P, Zhang X, Prabhu JS, Pandey V. Therapeutic vulnerabilities in triple negative breast cancer: Stem-like traits explored within molecular classification. Biomed Pharmacother. 2024;174:116584.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"16530_CR4","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.3390\/cancers13122978","volume":"13","author":"CJ Li","year":"2021","unstructured":"Li CJ, Tzeng YT, Chiu YH, Lin HY, Hou MF, Chu PY. Pathogenesis and potential therapeutic targets for triple-negative breast cancer. Cancers (Basel). 2021;13(12):2978.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"16530_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.21037\/cco-19-230","volume":"10","author":"HA Azim","year":"2021","unstructured":"Azim HA, Kassem L, Azim H Jr. Integrating PARP inhibitors into the management of breast cancer: where are we? Chin Clin Oncol. 2021;10(5):50.","journal-title":"Chin Clin Oncol"},{"issue":"12","key":"16530_CR6","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1002\/cncr.31307","volume":"124","author":"AA Turk","year":"2018","unstructured":"Turk AA, Wisinski KB. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Cancer. 2018;124(12):2498\u2013506.","journal-title":"Cancer"},{"issue":"12","key":"16530_CR7","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.3390\/ijms19123793","volume":"19","author":"M C\u00e9saire","year":"2018","unstructured":"C\u00e9saire M, Thariat J, Cand\u00e9ias SM, Stefan D, Saintigny Y, Chevalier F, Combining PARP. inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer? Int J Mol Sci. 2018;19(12):3793.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"16530_CR8","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1158\/1535-7163.MCT-17-0256","volume":"19","author":"PH Park","year":"2020","unstructured":"Park PH, Yamamoto TM, Li H, Alcivar AL, Xia B, Wang Y, Bernhardy AJ, Turner KM, Kossenkov AV, Watson ZL, et al. Amplification of the mutation-carrying BRCA2 allele promotes RAD51 loading and PARP inhibitor resistance in the absence of reversion mutations. Mol Cancer Ther. 2020;19(2):602\u201313.","journal-title":"Mol Cancer Ther"},{"key":"16530_CR9","doi-asserted-by":"publisher","first-page":"106162","DOI":"10.1016\/j.phrs.2022.106162","volume":"178","author":"N Gupta","year":"2022","unstructured":"Gupta N, Huang TT, Horibata S, Lee JM. Cell cycle checkpoints and beyond: Exploiting the ATR\/CHK1\/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer. Pharmacol Res. 2022;178:106162.","journal-title":"Pharmacol Res"},{"key":"16530_CR10","doi-asserted-by":"publisher","first-page":"114770","DOI":"10.1016\/j.biopha.2023.114770","volume":"163","author":"XF Yi","year":"2023","unstructured":"Yi XF, Gao RL, Sun L, Wu ZX, Zhang SL, Huang LT, Han CB, Ma JT. Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: A counterbalance between anti-tumor and pro-tumor. Biomed Pharmacother. 2023;163:114770.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"16530_CR11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/onc.2017.311","volume":"37","author":"H Yamaguchi","year":"2018","unstructured":"Yamaguchi H, Du Y, Nakai K, Ding M, Chang SS, Hsu JL, Yao J, Wei Y, Nie L, Jiao S, et al. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. Oncogene. 2018;37(2):208\u201317.","journal-title":"Oncogene"},{"issue":"10","key":"16530_CR12","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1158\/0008-5472.CAN-24-2531","volume":"85","author":"F Pedretti","year":"2025","unstructured":"Pedretti F, Abdalfttah M, Pellegrino B, Mateo F, Mart\u00ednez-Sanz P, Herencia-Ropero A, \u00d2dena A, Clavell-Revelles P, Casali G, Dom\u00e8nech H, et al. Harnessing STING signaling and natural killer cells overcomes PARP inhibitor resistance in homologous recombination-deficient breast cancer. Cancer Res. 2025;85(10):1888\u2013908.","journal-title":"Cancer Res"},{"issue":"3","key":"16530_CR13","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.7150\/ijbs.121033","volume":"22","author":"X Hao","year":"2026","unstructured":"Hao X, Chao Z, Peng H, Guo X, Zheng S, Zhang C, Ding H, Wang Y, Xi Z, Gao Y, et al. Metformin sensitizes PTEN-deficient prostate cancer to PARP inhibitors by rebuilding NADP+ homeostasis. Int J Biol Sci. 2026;22(3):1346\u201368.","journal-title":"Int J Biol Sci"},{"key":"16530_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jclinepi.2018.05.021","volume":"101","author":"JM Losilla","year":"2018","unstructured":"Losilla JM, Oliveras I, Marin-Garcia JA, Vives J. Three risk of bias tools lead to opposite conclusions in observational research synthesis. J Clin Epidemiol. 2018;101:61\u201372.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"16530_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cell.2018.03.042","volume":"173","author":"C Hutter","year":"2018","unstructured":"Hutter C, Zenklusen JC. The Cancer Genome Atlas: Creating lasting value beyond its data. Cell. 2018;173(2):283\u20135.","journal-title":"Cell"},{"key":"16530_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"issue":"20","key":"16530_CR17","doi-asserted-by":"publisher","first-page":"10916","DOI":"10.1002\/ece3.6747","volume":"10","author":"CJ Lortie","year":"2020","unstructured":"Lortie CJ, Filazzola A. A contrast of meta and metafor packages for meta-analyses in R. Ecol Evol. 2020;10(20):10916\u201321.","journal-title":"Ecol Evol"},{"issue":"6","key":"16530_CR18","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.ajcnut.2024.08.016","volume":"120","author":"CE Orsso","year":"2024","unstructured":"Orsso CE, Caretero A, Poltronieri TS, Arends J, de van der Schueren MA, Kiss N, Laviano A, Prado CM. Effects of high-protein supplementation during cancer therapy: a systematic review and meta-analysis. Am J Clin Nutr. 2024;120(6):1311\u201324.","journal-title":"Am J Clin Nutr"},{"issue":"7121","key":"16530_CR19","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1136\/bmj.315.7121.1533","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ. 1997;315(7121):1533\u20137.","journal-title":"BMJ"},{"issue":"7","key":"16530_CR20","doi-asserted-by":"publisher","first-page":"100167","DOI":"10.1016\/j.modpat.2023.100167","volume":"36","author":"A Krishnan","year":"2023","unstructured":"Krishnan A, Spegg V, Dettwiler S, Schraml P, Moch H, Dedes K, Varga Z, Altmeyer M. Analysis of the PARP1, ADP-ribosylation, and TRIP12 triad with markers of patient outcome in human breast cancer. Mod Pathol. 2023;36(7):100167.","journal-title":"Mod Pathol"},{"issue":"2","key":"16530_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10549-024-07436-1","volume":"208","author":"Z Wang","year":"2024","unstructured":"Wang Z, Lu Y, Han M, Li A, Ruan M, Tong Y, Yang C, Zhang X, Zhu C, Wang C, et al. Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer. Breast Cancer Res Treat. 2024;208(2):429\u201340.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"16530_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10549-014-3230-1","volume":"149","author":"AR Green","year":"2015","unstructured":"Green AR, Caracappa D, Benhasouna AA, Alshareeda A, Nolan CC, Macmillan RD, Madhusudan S, Ellis IO, Rakha EA. Biological and clinical significance of PARP1 protein expression in breast cancer. Breast Cancer Res Treat. 2015;149(2):353\u201362.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"16530_CR23","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s10549-017-4552-6","volume":"167","author":"RC Brianese","year":"2018","unstructured":"Brianese RC, Nakamura KDM, Almeida FGDSR, Ramalho RF, Barros BDF, Ferreira ENE, Formiga MNDC, de Andrade VP, de Lima VCC, Carraro DM. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation. Breast Cancer Res Treat. 2018;167(3):803\u201314.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"16530_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10549-020-05647-w","volume":"181","author":"A Kawachi","year":"2020","unstructured":"Kawachi A, Yamashita S, Okochi-Takada E, Hirakawa A, Tsuda H, Shimomura A, Kojima Y, Yonemori K, Fujiwara Y, Kinoshita T, et al. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib\/eribulin combination therapy. Breast Cancer Res Treat. 2020;181(2):323\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"16530_CR25","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/s44321-024-00094-2","volume":"16","author":"Y Tai","year":"2024","unstructured":"Tai Y, Chow A, Han S, Coker C, Ma W, Gu Y, Estrada Navarro V, Kandpal M, Hibshoosh H, Kalinsky K, et al. FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer. EMBO Mol Med. 2024;16(8):1957\u201380.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"16530_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-025-07861-w","volume":"215","author":"F Ghasemi","year":"2025","unstructured":"Ghasemi F, Arima J, Takabe K. High PARP1 expression is associated with proliferative tumor biology in breast cancer. Breast Cancer Res Treat. 2025;215(1):21.","journal-title":"Breast Cancer Res Treat"},{"issue":"18","key":"16530_CR27","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1158\/1078-0432.CCR-20-0638","volume":"26","author":"N Vidula","year":"2020","unstructured":"Vidula N, Dubash T, Lawrence MS, Simoneau A, Niemierko A, Blouch E, Nagy B, Roh W, Chirn B, Reeves BA, et al. Identification of somatically acquired BRCA1\/2 mutations by cfDNA analysis in patients with metastatic breast cancer. Clin Cancer Res. 2020;26(18):4852\u201362.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"16530_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41523-023-00540-3","volume":"9","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Liu Z, Gui L, Yun W, Mao C, Deng R, Yao Y, Yu Q, Feng J, Ma H, et al. Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer. NPJ Breast Cancer. 2023;9(1):34.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"16530_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12943-025-02422-7","volume":"24","author":"X Peng","year":"2025","unstructured":"Peng X, Wang Y, Yu Z, Huang S, Zhang S, Zhong Z, Wang Y, Liu S, Wang K, Nicot C, et al. Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer. Mol Cancer. 2025;24(1):217.","journal-title":"Mol Cancer"},{"issue":"2","key":"16530_CR30","doi-asserted-by":"publisher","first-page":"e0118002","DOI":"10.1371\/journal.pone.0118002","volume":"10","author":"S Nagasawa","year":"2015","unstructured":"Nagasawa S, Sedukhina AS, Nakagawa Y, Maeda I, Kubota M, Ohnuma S, Tsugawa K, Ohta T, Roche-Molina M, Bernal JA, et al. LSD1 overexpression is associated with poor prognosis in basal-like breast cancer, and sensitivity to PARP inhibition. PLoS ONE. 2015;10(2):e0118002.","journal-title":"PLoS ONE"},{"issue":"21","key":"16530_CR31","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1158\/1078-0432.CCR-22-0749","volume":"28","author":"F Batalini","year":"2022","unstructured":"Batalini F, Gulhan DC, Mao V, Tran A, Polak M, Xiong N, Tayob N, Tung NM, Winer EP, Mayer EL, et al. Mutational signature 3 detected from clinical panel sequencing is associated with responses to olaparib in breast and ovarian cancers. Clin Cancer Res. 2022;28(21):4714\u201323.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"16530_CR32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.clbc.2021.12.007","volume":"22","author":"EM Walsh","year":"2022","unstructured":"Walsh EM, Mangini N, Fetting J, Armstrong D, Chan IS, Connolly RM, Fiallos K, Lehman J, Nunes R, Petry D, et al. Olaparib use in patients with metastatic breast cancer harboring somatic BRCA1\/2 mutations or mutations in non-BRCA1\/2, DNA damage repair genes. Clin Breast Cancer. 2022;22(4):319\u201325.","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"16530_CR33","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10549-021-06292-7","volume":"189","author":"J Xu","year":"2021","unstructured":"Xu J, Keenan TE, Overmoyer B, Tung NM, Gelman RS, Habin K, Garber JE, Ellisen LW, Winer EP, Goss PE, et al. Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1\/2 mutations. Breast Cancer Res Treat. 2021;189(3):641\u201351.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"16530_CR34","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12282-021-01319-9","volume":"29","author":"A Sueta","year":"2022","unstructured":"Sueta A, Yamamoto-Ibusuki M, Tomiguchi M, Fujiki Y, Goto-Yamaguchi L, Iwase H, Yamamoto Y. Predictive and prognostic significance of BRCAness in HER2-negative breast cancer. Breast Cancer. 2022;29(2):368\u201376.","journal-title":"Breast Cancer"},{"key":"16530_CR35","doi-asserted-by":"publisher","unstructured":"Jahan N, Taraba J, Boddicker NJ, Giridhar KV, Leon-Ferre RA, Tevaarwerk AJ, Cathcart-Rake E, O\u2019Sullivan CC, Peethambaram PP, Hobday TJ et al. Real-world evidence on prescribing patterns and clinical outcomes of metastatic breast cancer patients treated with PARP inhibitors: The Mayo Clinic experience. Clin Breast Cancer. 2025;25(3):e211-e219.e2. https:\/\/doi.org\/10.1016\/j.clbc.2024.10.006.","DOI":"10.1016\/j.clbc.2024.10.006"},{"issue":"1","key":"16530_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41523-024-00667-x","volume":"10","author":"PA Fasching","year":"2024","unstructured":"Fasching PA, Hu C, Hart SN, Ruebner M, Polley EC, Gnanaolivu RD, Hartkopf AD, Huebner H, Janni W, Hadji P, et al. Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer. NPJ Breast Cancer. 2024;10(1):57.","journal-title":"NPJ Breast Cancer"},{"issue":"24","key":"16530_CR37","doi-asserted-by":"publisher","first-page":"6818","DOI":"10.1158\/0008-5472.CAN-18-0633","volume":"78","author":"R Ali","year":"2018","unstructured":"Ali R, Al-Kawaz A, Toss MS, Green AR, Miligy IM, Mesquita KA, Seedhouse C, Mirza S, Band V, Rakha EA, et al. Targeting PARP1 in XRCC1-deficient sporadic invasive breast cancer or preinvasive ductal carcinoma in situ induces synthetic lethality and chemoprevention. Cancer Res. 2018;78(24):6818\u201327.","journal-title":"Cancer Res"},{"key":"16530_CR38","doi-asserted-by":"publisher","first-page":"880643","DOI":"10.3389\/fonc.2022.880643","volume":"12","author":"N Mekonnen","year":"2022","unstructured":"Mekonnen N, Yang H, Shin YK. Homologous recombination deficiency in ovarian, breast, colorectal, pancreatic, non-small cell lung and prostate cancers, and the mechanisms of resistance to PARP inhibitors. Front Oncol. 2022;12:880643.","journal-title":"Front Oncol"},{"issue":"12","key":"16530_CR39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s12032-022-01840-7","volume":"39","author":"SD Kaur","year":"2022","unstructured":"Kaur SD, Chellappan DK, Aljabali AA, Tambuwala M, Dua K, Kapoor DN. Recent advances in cancer therapy using PARP inhibitors. Med Oncol. 2022;39(12):241.","journal-title":"Med Oncol"},{"issue":"Suppl 2","key":"16530_CR40","first-page":"6","volume":"12","author":"K Hanna","year":"2021","unstructured":"Hanna K, Mayden K. Chemotherapy treatment considerations in metastatic breast cancer. J Adv Pract Oncol. 2021;12(Suppl 2):6\u201312.","journal-title":"J Adv Pract Oncol"},{"key":"16530_CR41","doi-asserted-by":"publisher","first-page":"103858","DOI":"10.1016\/j.dnarep.2025.103858","volume":"152","author":"S Wang","year":"2025","unstructured":"Wang S, Wu Y, Zong W, Wang ZQ. Yin-Yang of PARP1 in genotoxic and inflammatory response. DNA Repair (Amst). 2025;152:103858.","journal-title":"DNA Repair (Amst)"},{"issue":"8","key":"16530_CR42","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1158\/0008-5472.CAN-18-3631","volume":"79","author":"T Ubhi","year":"2019","unstructured":"Ubhi T, Brown GW. Exploiting DNA replication stress for cancer treatment. Cancer Res. 2019;79(8):1730\u20139.","journal-title":"Cancer Res"},{"issue":"5","key":"16530_CR43","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1007\/s13277-015-4465-0","volume":"37","author":"A Mazzotta","year":"2016","unstructured":"Mazzotta A, Partipilo G, De Summa S, Giotta F, Simone G, Mangia A. Nuclear PARP1 expression and its prognostic significance in breast cancer patients. Tumour Biol. 2016;37(5):6143\u201353.","journal-title":"Tumour Biol"},{"issue":"8","key":"16530_CR44","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/jcp.31015","volume":"238","author":"J Wooten","year":"2023","unstructured":"Wooten J, Mavingire N, Damar K, Loaiza-Perez A, Brantley E. Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer. J Cell Physiol. 2023;238(8):1625\u201340.","journal-title":"J Cell Physiol"},{"issue":"12","key":"16530_CR45","doi-asserted-by":"publisher","first-page":"4728","DOI":"10.1002\/jcb.26140","volume":"118","author":"C Liu","year":"2017","unstructured":"Liu C, Chang H, Li XH, Qi YF, Wang JO, Zhang Y, Yang XH. Network meta-analysis on the effects of DNA damage response-related gene mutations on overall survival of breast cancer based on TCGA database. J Cell Biochem. 2017;118(12):4728\u201334.","journal-title":"J Cell Biochem"},{"issue":"40","key":"16530_CR46","doi-asserted-by":"publisher","first-page":"e4975","DOI":"10.1097\/MD.0000000000004975","volume":"95","author":"Z Baretta","year":"2016","unstructured":"Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Med (Baltim). 2016;95(40):e4975.","journal-title":"Med (Baltim)"},{"key":"16530_CR47","doi-asserted-by":"publisher","first-page":"5830475","DOI":"10.1155\/2022\/5830475","volume":"2022","author":"C Shao","year":"2022","unstructured":"Shao C, Chang MS, Lam FC, Marley AR, Tang H, Song Y, Miller C, Brown M, Wan I, Han J, et al. A systematic review and meta-analysis on the prognostic value of BRCA mutations, homologous recombination gene mutations, and homologous recombination deficiencies in cancer. J Oncol. 2022;2022:5830475.","journal-title":"J Oncol"},{"issue":"3","key":"16530_CR48","doi-asserted-by":"publisher","first-page":"186","DOI":"10.56875\/2589-0646.1033","volume":"16","author":"R Kunwor","year":"2023","unstructured":"Kunwor R, Silver DP, Abu-Khalaf M. PARP inhibitors for the treatment of BRCA1\/2-mutated metastatic breast cancer: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2023;16(3):186\u201396.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"7","key":"16530_CR49","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.ejca.2008.03.006","volume":"44","author":"CN Oldenhuis","year":"2008","unstructured":"Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer. 2008;44(7):946\u201353.","journal-title":"Eur J Cancer"},{"issue":"8","key":"16530_CR50","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3390\/cimb47080638","volume":"47","author":"B Shah","year":"2025","unstructured":"Shah B, Hussain M, Seth A. Homologous recombination deficiency in ovarian and breast cancers: Biomarkers, diagnosis, and treatment. Curr Issues Mol Biol. 2025;47(8):638.","journal-title":"Curr Issues Mol Biol"},{"issue":"11 Suppl","key":"16530_CR51","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1002\/(SICI)1097-0142(19991201)86:11+<2575::AID-CNCR15>3.0.CO;2-F","volume":"86","author":"SL Neuhausen","year":"1999","unstructured":"Neuhausen SL. Ethnic differences in cancer risk resulting from genetic variation. Cancer. 1999;86(11 Suppl):2575\u201382.","journal-title":"Cancer"},{"key":"16530_CR52","doi-asserted-by":"publisher","first-page":"16013","DOI":"10.3389\/bjbs.2026.16013","volume":"83","author":"C Eze","year":"2026","unstructured":"Eze C, Swadi R, Ross K, Sharma V. Breast cancer disparities in African and African-ancestry populations: Genetics, epigenetics, structural barriers and technology-enabled solutions. Br J Biomed Sci. 2026;83:16013.","journal-title":"Br J Biomed Sci"},{"key":"16530_CR53","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jclinepi.2021.05.007","volume":"136","author":"O Dewidar","year":"2021","unstructured":"Dewidar O, Riddle A, Ghogomu E, Hossain A, Arora P, Bhutta ZA, Black RE, Cousens S, Gaffey MF, Mathew C, et al. PRIME-IPD SERIES Part 1. The PRIME-IPD tool promoted verification and standardization of study datasets retrieved for IPD meta-analysis. J Clin Epidemiol. 2021;136:227\u201334.","journal-title":"J Clin Epidemiol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16530-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16530-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16530-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:32:43Z","timestamp":1791498763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16530-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16530"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16530-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1210"}}